Skip to main content
main-content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

08-18-2017 | Adalimumab | News

Finger prick test has potential to monitor adalimumab response

Patients with inflammatory arthritis who are treated with adalimumab could monitor their blood levels of the drug using a finger prick test in place of full intravenous blood draws, researchers report.

08-04-2017 | Rheumatoid arthritis | Article

At a glance: The ORAL trials of tofacitinib for the treatment of RA

Our quick-reference guide to the seven ORAL trials of tofacitinib for the treatment of rheumatoid arthritis that have been completed to date.

08-16-2017 | Juvenile idiopathic arthritis | Editorial | Article

What’s in a name: The complexity of juvenile idiopathic arthritis

The complexity of juvenile idiopathic arthritis is discussed here by Editorial Board member Sangeeta Sule, focusing on how clinical decisions can be better informed in order to provide more precise and personalized treatment options.

Latest from across the site

08-18-2017 | Systemic lupus erythematosus | News

Hopes revived for CD40L blockade in SLE

Phase I trial results suggest that the CD40 ligand inhibitor dapirolizumab pegol is well tolerated and elicits a clinical response in patients with systemic lupus erythematosus.

Source:

Ann Rheum Dis 2017; Advance online publication

08-18-2017 | Adalimumab | News

Finger prick test has potential to monitor adalimumab response

Patients with inflammatory arthritis who are treated with adalimumab could monitor their blood levels of the drug using a finger prick test in place of full intravenous blood draws, researchers report.

Source:

Br J Clin Pharmacol 2017; Advance online publication

08-16-2017 | Juvenile idiopathic arthritis | Editorial | Article

What’s in a name: The complexity of juvenile idiopathic arthritis

The complexity of juvenile idiopathic arthritis is discussed here by Editorial Board member Sangeeta Sule, focusing on how clinical decisions can be better informed in order to provide more precise and personalized treatment options.

Author:
Sangeeta Sule

08-16-2017 | Osteoarthritis | News

Decrease in walking speed predicts future OA risk

Results from an Osteoarthritis Initiative study suggest that people whose walking speed slows down over a 1-year period have an increased risk for developing knee osteoarthritis over the following 2 years compared with those who maintain a consistent pace.

Source:

J Rheumatol 2017; 44: 1265–1270

08-14-2017 | Rheumatoid arthritis | News

News in brief

PRO results support baricitinib for RA patients

Secondary analyses of the RA-BEAM trial suggest that the clinical improvements experienced by rheumatoid arthritis patients treated with baricitinib are accompanied by corresponding gains in patient-reported outcomes.

08-11-2017 | Rheumatoid arthritis | News

News in brief

Equivalent efficacy of leflunomide and low-dose rituximab shown in RA

Results of a Sri Lankan trial suggest that leflunomide and low-dose rituximab have comparable efficacy when used in combination with methotrexate for the treatment of patients with rheumatoid arthritis refractory to first-line non-biologic disease modifying antirheumatic drugs.

Latest from us on Twitter

Meet our Editorial Board

image credits